Thierry Chardes
Paris, 75016, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications
Anti-cathepsin D antibody-drug conjugates for the targeted delivery of monomethyl auristatin F and E elicit potent anticancer activity in breast cancer.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: August 07, 2025
Antibodies against the multifaceted cathepsin D protein open new avenues for TNBC immunotherapy.
Journal: Journal for immunotherapy of cancer
Published: December 02, 2024
Correction: The anti-HER3 (ErbB3) therapeutic antibody 9F7-F11 induces HER3 ubiquitination and degradation in tumors through JNK1/2- dependent ITCH/AIP4 activation.
Journal: Oncotarget
Published: October 11, 2024
Cathepsins: Novel opportunities for antibody therapeutics in cancer.
Journal: British journal of pharmacology
Published: August 08, 2024
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
Journal: Journal for immunotherapy of cancer
Published: December 19, 2023
Anti-cathepsin D immunotherapy triggers both innate and adaptive anti-tumour immunity in breast cancer.
Journal: British journal of pharmacology
Published: June 28, 2023
Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer.
Journal: Frontiers in immunology
Published: February 17, 2023
SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity.
Journal: International journal of cancer
Published: December 14, 2021
Improving Biologics' Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures.
Journal: Cancers
Published: July 08, 2021
A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment.
Journal: Theranostics
Published: January 15, 2021
Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival.
Journal: International journal of oncology
Published: October 12, 2020
Last Updated: 09/26/2026